City Therapeutics advanced its public-market visibility with a $200 million IPO aimed at pushing RNA interference therapies beyond the liver, a key hurdle for systemic delivery. The company’s pipeline includes programs in or nearing clinical testing and earlier research built around tissue-distribution approaches intended to broaden target reach. The offering also signals intensifying competition in RNAi “Alnylam 2.0” territory, where delivery, dosing durability, and target pharmacology increasingly determine which platforms can challenge established modalities. For investors and partners, the IPO provides a clearer funding bridge for clinical expansion and potential combination strategies. Separately, the Estuary Biotherapeutics fundraising in inherited disease highlights that while modalities compete, capital remains available for differentiated delivery and genetic medicine architectures—especially when near-term clinical pathways can be articulated.